News for Repligen Corporation (RGEN)

908 Devices (MASS) stock soars 71% premarket as Repligen (RGEN) announces $70M acquisition of its bioprocessing analytics portfolio. Read more here.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarte

**media[556718]**

Explore Repligen's Q4 2024 earnings insights, highlighting strong non-COVID growth, standout CDMO performance, innovative product launches, and optimistic...

Repligen (RGEN) delivered earnings and revenue surprises of 7.32% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[545491]**

**media[537520]**

TD Cowen has started coverage of Repligen (RGEN) with a buy rating, citing the company's limited exposure to NIH funding cuts and China.  Read more here.

Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today a

Next-Generation At-Line Concentration Measurement for Bioprocessing WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN), a life sc

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded...

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the letter can be downloaded here.

Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (RGEN)

Repligen director Hunt sells $3.39 million in stock

Repligen Corporation (NASDAQ:RGEN) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ETCompany ParticipantsSondra Newman - Vice President,...

RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.

Repligen Corporation (RGEN) is stealing the spotlight after reporting a standout third quarter, with revenue climbing 10% year-over-year to $155 million. The bi